Percentage of responders, i.e., patients with 2-point decrease in visual analog scale pain severity at each efficacy timepoint.
| Group | 2-month Proportion (95% CI) | 3-month Proportion (95% CI) | 4-month Proportion (95% CI) |
|---|---|---|---|
| IA-BoNT/A | 71 (49, 92) | 62 (41, 83) | 50 (27, 73) |
| IA-placebo | 35 (15, 54) | 43 (22, 64) | 55 (33, 77) |
| Difference (IA-BoNT/A–IA-placebo)* | 36 (7, 65) | 19 (−11, 49) | −5 (−37, 27) |
↵* The difference between botulinum toxin and placebo groups was statistically significant at 2 months (p = 0.025). The difference between botulinum toxin and placebo groups was also statistically significant when all 3 timepoints (2, 3 and 4 months) were included (p = 0.019), using generalized estimating equations analyses.